STOCK TITAN

XORTX Therapeutics Inc - XRTX STOCK NEWS

Welcome to our dedicated news page for XORTX Therapeutics (Ticker: XRTX), a resource for investors and traders seeking the latest updates and insights on XORTX Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect XORTX Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of XORTX Therapeutics's position in the market.

Rhea-AI Summary
XORTX Therapeutics reschedules special meeting of shareholders to consider share consolidation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.81%
Tags
none
-
Rhea-AI Summary
XORTX Therapeutics cancels special meeting of shareholders and plans to reschedule. The meeting was called to consider a share consolidation to regain compliance with NASDAQ listing requirements. The cancellation is due to a significant change in shareholder base and potential misleading proxy solicitation activities. XORTX believes a NASDAQ listing is important for liquidity and funding.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.65%
Tags
none
-
Rhea-AI Summary
XORTX Therapeutics Inc. announces a special meeting of shareholders to consider a share consolidation for compliance with NASDAQ listing requirements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.4%
Tags
none
Rhea-AI Summary
XORTX Therapeutics announces acceptance of abstract on the effect of lowering uric acid on PKD in mice, to be presented at ASN meeting. Results suggest uric acid lowering is necessary for therapeutic benefit. Positive for XORTX's innovative therapies for kidney disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
XORTX Therapeutics Inc. announces participation in upcoming investor conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.86%
Tags
conferences
-
Rhea-AI Summary
XORTX Therapeutics Inc. announces participation in Kidney Foundation's 'Kidney March' to support chronic kidney disease research
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.28%
Tags
none
Rhea-AI Summary
XORTX submits Orphan Drug Designation application for XORLO™ to the EMA for the treatment of ADPKD. Decision expected in December.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.77%
Tags
clinical trial
-
News
Rhea-AI Summary
XORTX Therapeutics Inc. appoints James Fairbairn as Chief Financial Officer, replacing Amar Keshri. Fairbairn previously served as the Company's CFO from November 2018 to July 2021. He has over 30 years of experience with publicly-traded companies and holds a CPA designation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.69%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
XORTX Therapeutics Inc

Nasdaq:XRTX

XRTX Rankings

XRTX Stock Data

10.72M
1.82M
4.08%
23.95%
0.36%
Support Activities for Nonmetallic Minerals (except Fuels) Mining
Mining, Quarrying, and Oil and Gas Extraction
Link
Canada
Calgary

About XRTX

xortx therapeutics inc., a bio-pharmaceutical company, focuses on the development and commercialization of therapies to treat progressive kidney diseases worldwide. it has two lead programs, including treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease. the company focuses on developing therapies for health consequences that includes pre-diabetes, diabetes, and cardiovascular disease. in addition, it develops uric acid lowering agents to treat diabetic nephropathy, hypertension, insulin resistance, metabolic syndrome, and diabetes; and xanthine oxidase inhibitors. the company has a strategic alliance with teijin pharma limited to develop tmx-049, a xanthine oxidoreductase; and a partnership with the icahn school of medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with covid-19. xortx therapeutics inc. is headquartered in calgary, canada.